Zobrazeno 1 - 10
of 56
pro vyhledávání: '"A R Cobitz"'
Autor:
Christine K. Bailey, Stephen Caltabiano, Alexander R. Cobitz, Chun Huang, Kelly M. Mahar, Vickas V. Patel
Publikováno v:
BMC Nephrology, Vol 20, Iss 1, Pp 1-12 (2019)
Abstract Background Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor currently being investigated as a treatment for anemia of chronic kidney disease (CKD) in both dialysis and nondialysis patients. In clinical studies to date,
Externí odkaz:
https://doaj.org/article/27bc2670a74349538c5d727bfabca1f7
Autor:
Heide A. Stirnadel-Farrant, Angelo Karaboyas, Borut Cizman, Brian A. Bieber, Lata Kler, Delyth Jones, Alexander R. Cobitz, Bruce M. Robinson
Publikováno v:
Kidney International Reports, Vol 4, Iss 6, Pp 864-872 (2019)
Introduction: Cardiovascular (CV) morbidity and mortality are excessively high among hemodialysis (HD) patients. Anemia is a common complication of chronic kidney disease (CKD) and a known risk factor for CV events. To understand the impact of the re
Externí odkaz:
https://doaj.org/article/87864e505ec240ba80546f280000f9ec
Publikováno v:
Kidney International Reports, Vol 3, Iss 4, Pp 841-850 (2018)
Introduction: Hyporesponsiveness to recombinant human erythropoietin (rhEPO) is a major problem affecting some patients with chronic kidney disease (CKD), predominantly those on hemodialysis (HD). Daprodustat (GSK1278863) is a hypoxia-inducible facto
Externí odkaz:
https://doaj.org/article/d52ce01df2734f54b89b9c72e96d04d5
Autor:
Heide A. Stirnadel-Farrant, Jiacong Luo, Lata Kler, Borut Cizman, Delyth Jones, Steven M. Brunelli, Alexander R. Cobitz
Publikováno v:
BMC Nephrology, Vol 19, Iss 1, Pp 1-11 (2018)
Abstract Background A combination of safety concerns and labeling changes impacted use of erythropoiesis-stimulating agents (ESAs) in renal anemia. Data regarding contemporary utilization in pre-dialysis chronic kidney disease (CKD) are lacking. Meth
Externí odkaz:
https://doaj.org/article/5804556e0b1444b3aa0c4dc29db12b46
Autor:
Daniel W. Coyne, Ajay K. Singh, Renato D. Lopes, Christine K. Bailey, Tara L. DiMino, Chun Huang, Jeffrey Connaire, Anjay Rastogi, Sung-Gyun Kim, Marcelo Orias, Sapna Shah, Vickas Patel, Alexander R. Cobitz, Christoph Wanner
Publikováno v:
Clinical Journal of the American Society of Nephrology. 17:1325-1336
Daprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being investigated for the treatment of anemia of CKD. In this noninferiority trial, we compared daprodustat administered three times weekly with epoetin alfa (epoetin)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2deecb99dbef179987732f8195919778
https://doi.org/10.2215/cjn.00550122
https://doi.org/10.2215/cjn.00550122
Autor:
Iain C. Macdougall, Amy Mewborn Meadowcroft, Allison Blackorby, BORUT Cizman, Alexander R Cobitz, Sergio Godoy, Vivekanand Jha, Kirsten L. Johansen, Gearoid McMahon, Gregorio T. Obrador, Muh Geot Wong, Ajay K. Singh
Publikováno v:
American Journal of Nephrology.
Introduction: Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) affects 10–15% of the chronic dialysis population. We explored baseline characteristics and predictors of ESA hyporesponsiveness in a global randomized cardiovascular outc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5818008713a0d69bc91a5180b1542d0
https://doi.org/10.1159/000528696
https://doi.org/10.1159/000528696
Autor:
Vlado Perkovic, Allison Blackorby, Borut Cizman, Kevin Carroll, Alexander R Cobitz, Rich Davies, Tara L DiMino, Vivekanand Jha, Kirsten L Johansen, Renato D Lopes, Lata Kler, Iain C Macdougall, John J V McMurray, Amy M Meadowcroft, Gregorio T Obrador, Scott Solomon, Lin Taft, Christoph Wanner, Sushrut S Waikar, David C Wheeler, Andrzej Wiecek, Ajay K Singh
Publikováno v:
Nephrology Dialysis Transplantation. 37:2157-2170
Background Anaemia is common in chronic kidney disease (CKD) and assessment of the risks and benefits of new therapies is important. Methods The Anaemia Study in CKD: Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Non-Dialysis (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3075e9cc099e0482ca71dd0d4da81a6f
https://doi.org/10.1093/ndt/gfab318
https://doi.org/10.1093/ndt/gfab318
Autor:
Ajay K Singh, Finnian R Mc Causland, Brian L Claggett, Christoph Wanner, Andrzej Wiecek, Michael B Atkins, Kevin Carroll, Vlado Perkovic, John J V McMurray, Janet Wittes, Steven Snapinn, Allison Blackorby, Amy Meadowcroft, Tara Barker, Tara DiMino, Stephen Mallett, Alexander R Cobitz, Scott D Solomon
Publikováno v:
Nephrology Dialysis Transplantation.
Background The prespecified on-treatment analysis of ASCEND-ND (NCT02876835) raised concerns about a higher relative risk of cancer-related adverse events (AEs) with daprodustat vs darbepoetin in patients with anaemia of CKD. This concern was not obs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9789a473ceaf2cb5b0d125cc7969194d
https://doi.org/10.1093/ndt/gfac342
https://doi.org/10.1093/ndt/gfac342
Autor:
A K Singh, A Acharya, K Carroll, R D Lopes, F R McCausland, L Mulloy, V Perkovic, S Solomon, S S Waikar, C Wanner, M G Wong, A R Cobitz, S A Mallett, B C Shaddinger, J J V McMurray
Publikováno v:
European Heart Journal. 43
Background There are limited contemporary data available regarding adjudicated causes of death in patients with chronic kidney disease (CKD). Prior studies have indicated that cardiovascular (CV) events are one of the most common causes of death amon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24edb70151341052045d6ff69eeea67f
https://doi.org/10.1093/eurheartj/ehac544.1053
https://doi.org/10.1093/eurheartj/ehac544.1053
Autor:
Masaomi Nangaku, Reiko Nagai, Kyo Kurata, Yukihiro Endo, Takashi Nagakubo, Hidetoshi Kanai, Nobuhiko Okuda, Alexander R. Cobitz
Publikováno v:
Therapeutic Apheresis and Dialysis. 25:979-987
Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia of chronic kidney disease. This phase 3 study evaluated the efficacy and safety of daprodustat in an uncontrolled cohort of 56 Japanese peritoneal dial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9eefcf18f78954e536529e009a81c45
https://doi.org/10.1111/1744-9987.13686
https://doi.org/10.1111/1744-9987.13686